Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study
SAN DIEGO, Dec. 1, 2025 /PRNewswire/ — Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, today announced the…
